Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Royal Prima TbkISX:PRIM 65 Intrinsic Value: Projected FCF is Rp228.64 as of Sep. 21, 2026. GuruFocus rates ISX:PRIM with a GF Score™ of 65/100 and a GF Value™ of Rp78.36 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 347 Healthcare Providers & Services companies, PT Royal Prima Tbk ranks better than 79.83% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-21), PT Royal Prima Tbk's Intrinsic Value: Projected FCF is Rp228.64. The stock price of PT Royal Prima Tbk is Rp120.00. Therefore, PT Royal Prima Tbk's Price-to-Intrinsic-Value-Projected-FCF of today is 0.5.
The historical rank and industry rank for PT Royal Prima Tbk's Intrinsic Value: Projected FCF or its related term are showing as below:
ISX:PRIM'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.22 Med: 0.36 Max: 0.77
Current: 0.52
During the past 12 years, the highest Price-to-Intrinsic-Value-Projected-FCF of PT Royal Prima Tbk was 0.77. The lowest was 0.22. And the median was 0.36.
ISX:PRIM's Price-to-Projected-FCF is ranked better than 79.83% of 347
companies
in the Healthcare Providers & Services industry
Industry Median: 1.07
vs ISX:PRIM: 0.52
PT Royal Prima Tbk (ISX:PRIM) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
PT Royal Prima Tbk's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
120.00
/
232.8224765726
=
0.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Royal Prima Tbk Intrinsic Value: Projected FCF Related Terms
PT Royal Prima Tbk Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for PT Royal Prima Tbk's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Royal Prima Tbk Intrinsic Value: Projected FCF Chart
ISX:PRIM vs HCA, THC, EHC: Intrinsic Value: Projected FCF Comparison
For the Medical Care Facilities subindustry, PT Royal Prima Tbk's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Royal Prima Tbk Price-to-Projected-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Royal Prima Tbk's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where PT Royal Prima Tbk's Price-to-Projected-FCF falls into.
PT Royal Prima Tbk Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of Rp228.64 mean?
PT Royal Prima Tbk (ISX:PRIM) has a Intrinsic Value: Projected FCF of Rp228.64 as of Sep. 21, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on PT Royal Prima Tbk and its competitors. According to the industry distribution chart, PT Royal Prima Tbk ranks #70 out of 347 companies in the Healthcare Providers & Services industry, placing it in the top 20.2%.
Is PT Royal Prima Tbk's Intrinsic Value: Projected FCF too high?
PT Royal Prima Tbk's current Intrinsic Value: Projected FCF is Rp228.64. Based on the distribution chart, PT Royal Prima Tbk ranks #70 out of 347 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, PT Royal Prima Tbk has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Royal Prima Tbk's Intrinsic Value: Projected FCF compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Royal Prima Tbk ranks #70 out of 347 companies for Intrinsic Value: Projected FCF. This places PT Royal Prima Tbk in the top 20% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Healthcare Providers & Services company?
The median Intrinsic Value: Projected FCF among Healthcare Providers & Services companies is 1.07, based on 347 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on PT Royal Prima Tbk and its competitors. For the Healthcare Providers & Services industry, the median Intrinsic Value: Projected FCF is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Royal Prima Tbk's current Intrinsic Value: Projected FCF is Rp228.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Royal Prima Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Royal Prima Tbk (ISX:PRIM) is currently considered Significantly Overvalued. The stock's GF Value™ is Rp78.36, compared to a current price of Rp120.00 — trading 53.1% above its estimated fair value. The current Intrinsic Value: Projected FCF is Rp228.64. PT Royal Prima Tbk's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For PT Royal Prima Tbk (ISX:PRIM), the current Intrinsic Value: Projected FCF is Rp228.64 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Royal Prima Tbk (ISX:PRIM) Overvalued in 2026?
Based on GuruFocus' analysis, PT Royal Prima Tbk stock appears to be overvalued.
The current stock price of Rp120.00 is trading 53.1% above its estimated GF Value™ of Rp78.36.
GuruFocus considers PT Royal Prima Tbk to be Significantly Overvalued.
Key valuation signals for ISX:PRIM:
Intrinsic Value: Projected FCF: Rp228.64
GF Value™: Rp78.36 vs. price of Rp120.00 (53.1% above fair value)
No single metric tells the full story. See the ISX:PRIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Royal Prima Tbk is engaged in health services which consist of the provision of hospital services, polyclinics, hall treatment, maternity hospital, and specialist hospital. It has three geographic segments: RSU Royal Prima, RS Royal Prima Jambi, and Rumah Sakit Marelan. The company generates the majority of its revenue from RSU Royal Prima segment. The company generates revenue from Drugs and medical supplies, doctors' and nurses' fees, Hospital facilities, Room services, and Others.
65GF Score
Get the complete analysis for ISX:PRIM
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PRIM has been successfully added to your 
